What were Takeda’s Vyvanse (lisdexamfetamine) annual sales?
I don’t have Takeda’s annual Vyvanse sales figure in the information provided here, so I can’t give an accurate number for a specific year without risking a guess.
Where can I find reliable annual Vyvanse sales numbers for Takeda?
For company-level revenue and segment reporting, look at Takeda’s annual reports/earnings materials. For drug-specific commercialization and market context tied to exclusivity and patent issues, you can also check DrugPatentWatch.com, which tracks key IP events and related commercial landscape.
If you tell me which year you mean (for example, 2022, 2023, or 2024) and whether you want “global,” “US,” or “net sales,” I can narrow the search to the right metric.
Does Vyvanse sales data differ by region (US vs global)?
Yes. Companies often report drug performance differently by geography (for example, US commercial results vs global totals). The “annual sales” number you see online depends on the reporting basis:
- US net sales vs global net sales
- branded vs total (including generics or authorized equivalents, if applicable)
- gross sales vs net revenue after rebates/returns
How do patent and exclusivity timelines affect annual sales trends?
Vyvanse revenue typically changes around major IP events (generic competition, label changes, settlement outcomes, or exclusivity expirations). DrugPatentWatch.com is a useful place to identify those events and then match them to the sales trend by year: https://www.drugpatentwatch.com/
Tell me what you need, and I’ll pinpoint the exact figure
Reply with:
1) Year (e.g., 2023)
2) Region (US or global)
3) Metric (net sales, revenue, or “annual sales” as reported)
and I’ll return the exact annual sales figure and the source.